Genetic polymorphisms of type-1 and type-2 inflammatory cytokines in ischaemic stroke

Vascular Disease Prevention

Volumn 5, Issue 2, 2008, Pages 89-103

  Marousi, Stella ^a,b   Ellul, John ^a   Karakantza, Marina ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Atherosclerosis; Cerebral ischaemia; Cytokines; Genetic variations; Inflammation; Polymorphisms; Stroke

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ATHEROSCLEROSIS; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; GENE FUNCTION; GENE LOCATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

EID: 43049125478     PISSN: 15672700     EISSN: None     Source Type: Journal    
DOI: 10.2174/156727008784223981     Document Type: Review

References (212)

1. Elkind MS, Sacco RL. Stroke risk factors and stroke prevention. Semin Neurol 1998; 18: 429-40.
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
3. Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. Stroke 2003; 34: 2518-32.
4. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281-91.
5. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-90.
6. van der Wal AC, Das PK, Bentz van de Berg D, van der Loos CM, Becker AE. Atherosclerotic lesions in humans. In situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest 1989; 61: 166-70.
7. Stemme S, Faber B, Holm J, et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 1995; 92: 3893-7.
8. Lappin MB, Campbell JD. The Th1-Th2 classification of cellular immune responses: concepts, current thinking and applications in haematological malignancy. Blood Rev 2000; 14: 228-39.
9. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998; 70: 83-243.
10. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12: 227-57.
11. Varadhachary AS, Monestier M, Salgame P. Reciprocal induction of IL-10 and IL-12 from macrophages by low-density lipoprotein and its oxidized forms. Cell Immunol 2001; 213: 45-51.
12. Uyemura K, Demer LL, Castle SC, et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996; 97: 2130-8.
13. Nakamura T, Lee RK, Nam SY, et al. Roles of IL-4 and IFN-gamma in stabilizing the T helper cell type 1 and 2 phenotype. J Immunol 1997; 158: 2648-53.
14. Hsieh CS, Heimberger AB, Gold JS, O'Garra A, Murphy KM. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. Proc Natl Acad Sci USA 1992; 89: 6065-9.
15. D'Andrea A, Aste-Amezaga M, Valiante NM, et al. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041-8.
16. Frostegard J, Ulfgren AK, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145: 33-43.
17. Osborn L, Hession C, Tizard R, et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989; 59: 1203-11.
18. Szekanecz Z, Shah MR, Pearce WH, Koch AE. Intercellular adhesion molecule-1 (ICAM-1) expression and soluble ICAM-1 (sICAM-1) production by cytokine-activated human aortic endothelial cells: a possible role for ICAM-1 and sICAM-1 in atherosclerotic aortic aneurysms. Clin Exp Immunol 1994; 98: 337-43.
19. Briscoe DM, Cotran RS, Pober JS. Effects of tumor necrosis factor, lipopolysaccharide, and IL-4 on the expression of vascular cell adhesion molecule-1 in vivo. Correlation with CD3+ T cell infiltration. J Immunol 1992; 149: 2954-60.
20. Chatelain R, Wollenberg A, Martin C, et al. IL-10 inhibits ICAM-1 expression on human Langerhans cells but not on keratinocytes, dermal endothelial cells or fibroblasts. Arch Dermatol Res 1998; 290: 477-82.
21. Zoellner H, Filonzi EL, Stanton HR, Layton JE, Hamilton JA. Human arterial smooth muscle cells synthesize granulocyte colony-stimulating factor in response to interleukin-1 alpha and tumor necrosis factor-alpha. Blood 1992; 80: 2805-10.
22. Filonzi EL, Zoellner H, Stanton H, Hamilton JA. Cytokine regulation of granulocyte-macrophage colony stimulating factor and macrophage colony-stimulating factor production in human arterial smooth muscle cells. Atherosclerosis 1993; 99: 241-52.
23. Hansson GK, Hellstrand M, Rymo L, Rubbia L, Gabbiani G. Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J Exp Med 1989; 170: 1595-608.
24. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991; 11: 1223-30.
25. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci 1995; 748: 501-7.
26. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997; 96: 396-9.
27. Osnes LT, Westvik AB, Joo GB, Okkenhaug C, Kierulf P. Inhibition of IL-1 induced tissue factor (TF) synthesis and procoagulant activity (PCA) in purified human monocytes by IL-4, IL-10 and IL-13. Cytokine 1996; 8: 822-7.
28. Herbert JM, Savi P, Laplace MC, Lale A. IL-4 inhibits LPS-, IL-1 beta- and TNF alpha-induced expression of tissue factor in endothelial cells and monocytes. FEBS Lett 1992; 310: 31-3.
29. Young JL, Libby P, Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 2002; 88: 554-67.
30. Gupta S, Pablo AM, Jiang X, et al. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997; 99: 2752-61.
31. Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein Edeficient mice. Am J Pathol 2003; 163: 1117-25.
32. Laurat E, Poirier B, Tupin E, et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2001; 104: 197-202.
33. Pinderski LJ, Fischbein MP, Subbanagounder G, et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002; 90: 1064-71.
34. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002; 252: 283-94.
35. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-5.
36. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001; 32: 917-24.
37. Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of Creactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001; 32: 2575-9.
38. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003; 108: 2317-22.
39. van Exel E, Gussekloo J, de Craen AJ, et al. Inflammation and stroke: the Leiden 85-Plus Study. Stroke 2002; 33: 1135-8.
40. Arvin B, Neville LF, Barone FC, Feuerstein GZ. The role of inflammation and cytokines in brain injury. Neurosci Biobehav Rev 1996; 20: 445-52.
41. Becker KJ. Inflammation and acute stroke. Curr Opin Neurol 1998; 11: 45-9.
42. DeGraba TJ. The role of inflammation after acute stroke: utility of pursuing anti-adhesion molecule therapy. Neurology 1998; 51: S62-8.
43. Jean WC, Spellman SR, Nussbaum ES, Low WC. Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. Neurosurgery 1998; 43: 1382-96; discussion 1396-7.
44. Stoll G, Jander S, Schroeter M. Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system. Adv Exp Med Biol 2002; 513: 87-113.
45. Tan KT, Lip GY, Blann AD. Post-stroke inflammatory response: effects of stroke evolution and outcome. Curr Atheroscler Rep 2003; 5: 245-51.
46. Danton GH, Dietrich WD. Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol 2003; 62: 127-36.
47. Allan SM, Rothwell NJ. Inflammation in central nervous system injury. Philos Trans R Soc Lond B Biol Sci 2003; 358: 1669-77.
48. Chamorro A. Role of inflammation in stroke and atherothrombosis. Cerebrovasc Dis 2004; 17 (Suppl 3): 1-5.
49. Correale J, Villa A. The neuroprotective role of inflammation in nervous system injuries. J Neurol 2004; 251: 1304-16.
50. Dietrich WD, Prado R, Watson BD, Nakayama H. Middle cerebral artery thrombosis: acute blood-brain barrier consequences. J Neuropathol Exp Neurol 1988; 47: 443-51.
51. Fassbender K, Mossner R, Motsch L, et al. Circulating selectinand immunoglobulin-type adhesion molecules in acute ischemic stroke. Stroke 1995; 26: 1361-4.
52. Bitsch A, Klene W, Murtada L, Prange H, Rieckmann P. A longitudinal prospective study of soluble adhesion molecules in acute stroke. Stroke 1998; 29: 2129-35.
53. Lindsberg PJ, Carpen O, Paetau A, Karjalainen-Lindsberg ML, Kaste M. Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circulation 1996; 94: 939-45.
54. Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992; 23: 1367-79.
55. Jander S, Kraemer M, Schroeter M, Witte OW, Stoll G. Lymphocytic infiltration and expression of intercellular adhesion molecule-1 in photochemically induced ischemia of the rat cortex. J Cereb Blood Flow Metab 1995; 15: 42-51.
56. Wang PY, Kao CH, Mui MY, Wang SJ. Leukocyte infiltration in acute hemispheric ischemic stroke. Stroke 1993; 24: 236-40.
57. Akopov SE, Simonian NA, Grigorian GS. Dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction and their correlation with brain tissue damage. Stroke 1996; 27: 1739-43.
58. Stoll G, Jander S. The role of microglia and macrophages in the pathophysiology of the CNS. Prog Neurobiol 1999; 58: 233-47.
59. Liu T, McDonnell PC, Young PR, et al. Interleukin-1 beta mRNA expression in ischemic rat cortex. Stroke 1993; 24: 1746-50; discussion 1750-1.
60. Botchkina GI, Meistrell ME, 3rd, Botchkina IL, Tracey KJ. Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia. Mol Med 1997; 3: 765-81.
61. Tomimoto H, Akiguchi I, Wakita H, et al. Glial expression of cytokines in the brains of cerebrovascular disease patients. Acta Neuropathol (Berl) 1996; 92: 281-7.
62. Tarkowski E, Rosengren L, Blomstrand C, et al. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995; 26: 1393-8.
63. Takeda H, Spatz M, Ruetzler C, et al. Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke-prone rats. Stroke 2002; 33: 2156-63.
64. Scherbel U, Raghupathi R, Nakamura M, et al. Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc Natl Acad Sci U S A 1999; 96: 8721-6.
65. Sairanen T, Carpen O, Karjalainen-Lindsberg ML, et al. Evolution of cerebral tumor necrosis factor-alpha production during human ischemic stroke. Stroke 2001; 32: 1750-8.
66. Arnett HA, Mason J, Marino M, et al. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001; 4: 1116-22.
67. Beamer NB, Coull BM, Clark WM, et al. Persistent inflammatory response in stroke survivors. Neurology 1998; 50: 1722-8.
68. Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stroke 1999; 30: 981-5.
69. Silvestri A, Vitale C, Ferretti F, et al. Plasma levels of inflammatory C-reactive protein and interleukin-6 predict outcome in elderly patients with stroke. J Am Geriatr Soc 2004; 52: 1586-7.
70. Waje-Andreassen U, Krakenes J, Ulvestad E, et al. IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand 2005; 111: 360-5.
71. Zaremba J, Losy J. Interleukin-18 in acute ischaemic stroke patients. Neurol Sci 2003; 24: 117-24.
72. Grau AJ, Reis A, Buggle F, et al. Monocyte function and plasma levels of interleukin-8 in acute ischemic stroke. J Neurol Sci 2001; 192: 41-7.
73. Ferrarese C, Mascarucci P, Zoia C, et al. Increased cytokine release from peripheral blood cells after acute stroke. J Cereb Blood Flow Metab 1999; 19: 1004-9.
74. Vila N, Castillo J, Davalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000; 31: 2325-9.
75. Fassbender K, Rossol S, Kammer T, et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci 1994; 122: 135-9.
76. Castellanos M, Castillo J, Garcia MM, et al. Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke 2002; 33: 982-7.
77. Intiso D, Zarrelli MM, Lagioia G, et al. Tumor necrosis factor alpha serum levels and inflammatory response in acute ischemic stroke patients. Neurol Sci 2004; 24: 390-6.
78. Vila N, Castillo J, Davalos A, et al. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke 2003; 34: 671-5.
79. Pelidou SH, Kostulas N, Matusevicius D, et al. High levels of IL-10 secreting cells are present in blood in cerebrovascular diseases. Eur J Neurol 1999; 6: 437-42.
80. Theodorou GL, Ellul J, Mougiou A, Mouzaki A, Karakantza M. A Shift from type-1 towards type-2 cytokine expression in peripheral blood T-cells in post-stroke patients: A beneficial modulatory effect to the progression of atherogenesis. Cerebrovasc Dis 2005; 19: 46.
81. Alberts MJ. Stroke genetics update. Stroke 2003; 34: 342-4.
82. Alberts MJ, Tournier-Lasserve E. Update on the genetics of stroke and cerebrovascular disease 2004. Stroke 2005; 36: 179-81.
83. Waters RJ, Nicoll JA. Genetic influences on outcome following acute neurological insults. Curr Opin Crit Care 2005; 11: 105-10.
84. DeGraba TJ. Immunogenetic susceptibility of atherosclerotic stroke: implications on current and future treatment of vascular inflammation. Stroke 2004; 35: 2712-9.
85. Dichgans M, Hegele RA. Update on the genetics of stroke and cerebrovascular disease 2006. Stroke 2007; 38: 216-8.
86. Um JY, Jeong HJ, Park RK, Hong SH, Kim HM. Aspects of gene polymorphisms in cerebral infarction: inflammatory cytokines. Cell Mol Life Sci 2005; 62: 824-33.
87. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-147.
88. Tarlow JK, Blakemore AI, Lennard A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91: 403-4.
89. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995; 99: 303-10.
90. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol 1998; 47: 195-8.
91. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992; 22: 396-402.
92. Dewberry R, Holden H, Crossman D, Francis S. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 2394-400.
93. Seripa D, Dobrina A, Margaglione M, et al. Relevance of interleukin-1 receptor antagonist intron-2 polymorphism in ischemic stroke. Cerebrovasc Dis 2003; 15: 276-81.
94. Um JY, Moon KS, Lee KM, Kim HM. Interleukin-1 gene cluster polymorphisms in cerebral infarction. Cytokine 2003; 23: 41-6.
95. Lee BC, Ahn SY, Doo HK, et al. Susceptibility for ischemic stroke in Korean population is associated with polymorphisms of the interleukin-1 receptor antagonist and tumor necrosis factor-alpha genes, but not the interleukin-1beta gene. Neurosci Lett 2004; 357: 33-6.
96. Balding J, Livingstone WJ, Pittock SJ, et al. The IL-6 G-174C polymorphism may be associated with ischaemic stroke in patients without a history of hypertension. Ir J Med Sci 2004; 173: 200-3.
97. Cvetkovic JT, Wiklund P, Ahmed E, et al. Polymorphisms of IL-1β, IL-1Ra, and TNF-α Genes: A Nested Case-Control Study of Their Association With Risk for Stroke. J Stroke Cerebrovasc Dis 2005; 14: 29-35.
98. Lalouschek W, Schillinger M, Hsieh K, et al. Polymorphisms of the inflammatory system and risk of ischemic cerebrovascular events. Clin Chem Lab Med 2006; 44: 918-23.
99. Lai J, Zhou D, Xia S, et al. Association of interleukin-1 gene cluster polymorphisms with ischemic stroke in a Chinese population. Neurol India 2006; 54: 366-9.
100. Worrall BB, Brott TG, Brown RD, Jr., et al. IL1RN VNTR polymorphism in ischemic stroke: analysis in 3 populations. Stroke 2007; 38: 1189-96.
101. Gromadzka G, Sarzynska-Dlugosz I, Czlonkowska A. IL1RN intron 2 polymorphism caused by variable number tandem repeats is associated with 1-year outcome in patients with ischaemic stroke. J Neurol Neurosurg Psychiatry 2007; 78: 183-6.
102. Nemetz A, Nosti-Escanilla MP, Molnar T, et al. IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Immunogenetics 1999; 49: 527-31.
103. Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 1998; 28: 2598-602.
104. Dziedzic T, Slowik A, Pera J, Szczudlik A. Lack of association between interleukin-1 beta polymorphism (-511) and ischaemic stroke. J Neurol Neurosurg Psychiatry 2004; 75: 170-1.
105. Iacoviello L, Di Castelnuovo A, Gattone M, et al. Polymorphisms of the interleukin-1beta gene affect the risk of myocardial infarction and ischemic stroke at young age and the response of mononuclear cells to stimulation in vitro. Arterioscler Thromb Vasc Biol 2005; 25: 222-7.
106. Dziedzic T, Slowik A, Pera J, Szczudlik A. Interleukin 1 beta polymorphism (-511) and risk of stroke due to small vessel disease. Cerebrovasc Dis 2005; 20: 299-303.
107. Rubattu S, Speranza R, Ferrari M, et al. A role of TNF-alpha gene variant on juvenile ischemic stroke: a case-control study. Eur J Neurol 2005; 12: 989-93.
108. Yamada Y, Metoki N, Yoshida H, et al. Genetic risk for ischemic and hemorrhagic stroke. Arterioscler Thromb Vasc Biol 2006; 26: 1920-5.
109. Zee RY, Cook NR, Cheng S, et al. Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. Hum Mol Genet 2004; 13: 389-96.
110. Berger K, Stogbauer F, Stoll M, et al. The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies. Hum Genet 2007; 121: 169-78.
111. Dominici R, Cattaneo M, Malferrari G, et al. Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1 alpha. Immunogenetics 2002; 54: 82-6.
112. Ishihara Y, Nishihara T, Kuroyanagi T, et al. Gingival crevicular interleukin-1 and interleukin-1 receptor antagonist levels in periodontally healthy and diseased sites. J Periodontal Res 1997; 32: 524-9.
113. Wilson AG, di Giovine FS, Blakemore AI, Duff GW. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992; 1: 353.
114. Abraham LJ, Kroeger KM. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol 1999; 66: 562-6.
115. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997; 34: 391-9.
116. Bouma G, Crusius JB, Oudkerk Pool M, et al. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996; 43: 456-63.
117. Kroeger KM, Steer JH, Joyce DA, Abraham LJ. Effects of stimulus and cell type on the expression of the -308 tumour necrosis factor promoter polymorphism. Cytokine 2000; 12: 110-9.
118. Braun N, Michel U, Ernst BP, et al. Gene polymorphism at position -308 of the tumor-necrosis-factor-alpha (TNF-alpha) in multiple sclerosis and it's influence on the regulation of TNF-alpha production. Neurosci Lett 1996; 215: 75-8.
119. Wu WS, McClain KL. DNA polymorphisms and mutations of the tumor necrosis factor-alpha (TNF-alpha) promoter in Langerhans cell histiocytosis (LCH). J Interferon Cytokine Res 1997; 17: 631-5.
120. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-9.
121. Brinkman BM, Zuijdeest D, Kaijzel EL, Breedveld FC, Verweij CL. Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J Inflamm 1995; 46: 32-41.
122. Bayley JP, de Rooij H, van den Elsen PJ, Huizinga TW, Verweij CL. Functional analysis of linker-scan mutants spanning the -376, -308, -244, and -238 polymorphic sites of the TNF-alpha promoter. Cytokine 2001; 14: 316-23.
123. Warle MC, Farhan A, Metselaar HJ, et al. Are cytokine gene polymorphisms related to in vitro cytokine production profiles? Liver Transpl 2003; 9: 170-81.
124. Stuber F, Udalova IA, Book M, et al. -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm 1995; 46: 42-50.
125. Um JY, Kim HM. Tumor necrosis factor alpha gene polymorphism is associated with cerebral infarction. Brain Res Mol Brain Res 2004; 122: 99-102.
126. Karahan ZC, Deda G, Sipahi T, Elhan AH, Akar N. TNF-alpha -308G/A and IL-6 -174 G/C polymorphisms in the Turkish pediatric stroke patients. Thromb Res 2005; 115: 393-8.
127. Grocott HP, White WD, Morris RW, et al. Genetic polymorphisms and the risk of stroke after cardiac surgery. Stroke 2005; 36: 1854-8.
128. Harcos P, Laki J, Kiszel P, et al. Decreased frequency of the TNF2 allele of TNF-alpha -308 promoter polymorphism is associated with lacunar infarction. Cytokine 2006; 33: 100-5.
129. Hoppe C, Klitz W, D'Harlingue K, et al. Confirmation of an association between the TNF(-308) promoter polymorphism and stroke risk in children with sickle cell anemia. Stroke 2007.
130. Knight JC, Udalova I, Hill AV, et al. A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nat Genet 1999; 22: 145-50.
131. Kaluza W, Reuss E, Grossmann S, et al. Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J Invest Dermatol 2000; 114: 1180-3.
132. Pociot F, D'Alfonso S, Compasso S, Scorza R, Richiardi PM. Functional analysis of a new polymorphism in the human TNF alpha gene promoter. Scand J Immunol 1995; 42: 501-4.
133. Skoog T, van't Hooft FM, Kallin B, et al. A common functional polymorphism (C - >A substitution at position -863) in the promoter region of the tumour necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha. Hum Mol Genet 1999; 8: 1443-9.
134. McCusker SM, Curran MD, Dynan KB, et al. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a case-control study. Lancet 2001; 357: 436-9.
135. Warzocha K, Ribeiro P, Bienvenu J, et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 1998; 91: 3574-81.
136. Messer G, Spengler U, Jung MC, et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 1991; 173: 209-19.
137. Pociot F, Briant L, Jongeneel CV, et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993; 23: 224-31.
138. Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996; 24: 381-4.
139. Um JY, An NH, Kim HM. TNF-alpha and TNF-beta gene polymorphisms in cerebral infarction. J Mol Neurosci 2003; 21: 167-71.
140. Furse RK, Kodys K, Zhu D, Miller-Graziano CL. Increased monocyte TNF-alpha message stability contributes to trauma patients' increased TNF production. J Leukoc Biol 1997; 62: 524-34.
141. Weinshenker BG, Hebrink D, Wingerchuk DM, et al. Genetic variants in the tumor necrosis factor receptor 1 gene in patients with MS. Neurology 1999; 52: 1500-3.
142. Komata T, Tsuchiya N, Matsushita M, Hagiwara K, Tokunaga K. Association of tumor necrosis factor receptor 2 (TNFR2) polymorphism with susceptibility to systemic lupus erythematosus. Tissue Antigens 1999; 53: 527-33.
143. Barton BE. The biological effects of interleukin 6. Med Res Rev 1996; 16: 87-109.
144. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994; 83: 113-8.
145. Rattazzi M, Puato M, Faggin E, et al. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens 2003; 21: 1787-803.
146. Qiu Z, Sweeney DD, Netzeband JG, Gruol DL. Chronic interleukin-6 alters NMDA receptor-mediated membrane responses and enhances neurotoxicity in developing CNS neurons. J Neurosci 1998; 18: 10445-56.
147. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-76.
148. Bennermo M, Held C, Stemme S, et al. Genetic predisposition of the interleukin-6 response to inflammation: implications for a variety of major diseases? Clin Chem 2004; 50: 2136-40.
149. Burzotta F, Iacoviello L, Di Castelnuovo A, et al. Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol 2001; 88: 1125-8.
150. Endler G, Marsik C, Joukhadar C, et al. The interleukin-6 G(-174)C promoter polymorphism does not determine plasma interleukin-6 concentrations in experimental endotoxemia in humans. Clin Chem 2004; 50: 195-200.
151. Nauck M, Winkelmann BR, Hoffmann MM, et al. The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction. J Mol Med 2002; 80: 507-13.
152. Schluter B, Raufhake C, Erren M, et al. Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 2002; 30: 32-7.
153. Kilpinen S, Hulkkonen J, Wang XY, Hurme M. The promoter polymorphism of the interleukin-6 gene regulates interleukin-6 production in neonates but not in adults. Eur Cytokine Netw 2001; 12: 62-8.
154. Brull DJ, Montgomery HE, Sanders J, et al. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001; 21: 1458-63.
155. Kubaszek A, Pihlajamaki J, Punnonen K, et al. The C-174G promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity. Diabetes 2003; 52: 558-61.
156. Jenny NS, Tracy RP, Ogg MS, et al. In the elderly, interleukin-6 plasma levels and the -174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol 2002; 22: 2066-71.
157. Rundek T, Elkind MS, Pittman J, et al. Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke 2002; 33: 1420-3.
158. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000; 275: 18138-44.
159. Acalovschi D, Wiest T, Hartmann M, et al. Multiple levels of regulation of the interleukin-6 system in stroke. Stroke 2003; 34: 1864-9.
160. Rivera-Chavez FA, Peters-Hybki DL, Barber RC, O'Keefe GE. Interleukin-6 promoter haplotypes and interleukin-6 cytokine responses. Shock 2003; 20: 218-23.
161. Greisenegger S, Endler G, Haering D, et al. The (-174) G/C polymorphism in the interleukin-6 gene is associated with the severity of acute cerebrovascular events. Thromb Res 2003; 110: 181-6.
162. Revilla M, Obach V, Cervera A, et al. A -174G/C polymorphism of the interleukin-6 gene in patients with lacunar infarction. Neurosci Lett 2002; 324: 29-32.
163. Chamorro A, Revilla M, Obach V, Vargas M, Planas AM. The -174G/C polymorphism of the interleukin 6 gene is a hallmark of lacunar stroke and not other ischemic stroke phenotypes. Cerebrovasc Dis 2005; 19: 91-5.
164. Yamaguchi S, Yamada Y, Metoki N, et al. Genetic risk for atherothrombotic cerebral infarction in individuals stratified by sex or conventional risk factors for atherosclerosis. Int J Mol Med 2006; 18: 871-83.
165. Pola R, Flex A, Gaetani E, et al. Synergistic effect of -174 G/C polymorphism of the interleukin-6 gene promoter and 469 E/K polymorphism of the intercellular adhesion molecule-1 gene in Italian patients with history of ischemic stroke. Stroke 2003; 34: 881-5.
166. Flex A, Gaetani E, Papaleo P, et al. Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke 2004; 35: 2270-5.
167. Dziedzic T, Gryz EA, Turaj W, Slowik A, Szczudlik A. Serum interleukin-6 soluble receptor in relation to interleukin-6 in stroke patients. J Mol Neurosci 2004; 24: 293-8.
168. Moreau M, Brocheriou I, Petit L, et al. Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation 1999; 99: 420-6.
169. Matsumoto T, Ikeda K, Mukaida N, et al. Prevention of cerebral edema and infarct in cerebral reperfusion injury by an antibody to interleukin-8. Lab Invest 1997; 77: 119-25.
170. Grau AJ, Aulmann M, Lichy C, et al. Increased cytokine release by leucocytes in survivors of stroke at young age. Eur J Clin Invest 2001; 31: 999-1006.
171. Vitetta ES, Ohara J, Myers CD, et al. Serological, biochemical, and functional identity of B cell-stimulatory factor 1 and B cell differentiation factor for IgG1. J Exp Med 1985; 162: 1726-31.
172. Rosenwasser LJ, Klemm DJ, Dresback JK, et al. Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy 1995; 25 (Suppl 2): 74-8; discussion 95-6.
173. Nakayama EE, Hoshino Y, Xin X, et al. Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype. J Virol 2000; 74: 5452-9.
174. Takabayashi A, Ihara K, Sasaki Y, et al. Novel polymorphism in the 5'-untranslated region of the interleukin-4 gene. J Hum Genet 1999; 44: 352-3.
175. Elliott K, Fitzpatrick E, Hill D, et al. The -590C/T and -34C/T interleukin-4 promoter polymorphisms are not associated with atopic eczema in childhood. J Allergy Clin Immunol 2001; 108: 285-7.
176. Shibata N, Ohnuma T, Takahashi T, et al. The effect of IL4 +33C/T polymorphism on risk of Japanese sporadic Alzheimer's disease. Neurosci Lett 2002; 323: 161-3.
177. Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL10 gene and further characterization of the 5' flanking sequence. Immunogenetics 1997; 46: 120-8.
178. Eskdale J, Gallagher G, Verweij CL, et al. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998; 95: 9465-70.
179. Rees LE, Wood NA, Gillespie KM, et al. The interleukin-10-1082 G/A polymorphism: allele frequency in different populations and functional significance. Cell Mol Life Sci 2002; 59: 560-9.
180. Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1-8.
181. Crawley E, Kay R, Sillibourne J, et al. Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999; 42: 1101-8.
182. Edwards-Smith CJ, Jonsson JR, Purdie DM, et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999; 30: 526-30.
183. Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP. Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun 2000; 1: 185-90.
184. George S, Ruan XZ, Navarrete C, et al. Renovascular disease is associated with low producer genotypes of the anti-inflammatory cytokine interleukin-10. Tissue Antigens 2004; 63: 470-5.
185. Fei GZ, Svenungsson E, Frostegard J, Padyukov L. The A-1087IL-10 allele is associated with cardiovascular disease in SLE. Atherosclerosis 2004; 177: 409-14.
186. Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737-42.
187. Cipollone F, Fazia M, Mincione G, et al. Increased expression of transforming growth factor-beta1 as a stabilizing factor in human atherosclerotic plaques. Stroke 2004; 35: 2253-7.
188. Dhandapani KM, Brann DW. Transforming growth factor-beta: a neuroprotective factor in cerebral ischemia. Cell Biochem Biophys 2003; 39: 13-22.
189. Schulick AH, Taylor AJ, Zuo W, et al. Overexpression of transforming growth factor beta1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. Proc Natl Acad Sci USA 1998; 95: 6983-8.
190. Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y. Association of a T29 - >C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000; 101: 2783-7.
191. Kim Y, Lee C. The gene encoding transforming growth factor beta 1 confers risk of ischemic stroke and vascular dementia. Stroke 2006; 37: 2843-5.
192. Sie MP, Uitterlinden AG, Bos MJ, et al. TGF-beta 1 polymorphisms and risk of myocardial infarction and stroke: the Rotterdam Study. Stroke 2006; 37: 2667-71.
193. Grainger DJ, Heathcote K, Chiano M, et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999; 8: 93-7.
194. Di Napoli M. Editorial comment--How to search for the role of genetic polymorphisms in stroke: theory vs practice. Stroke 2003; 34: 1869-70.
195. Prentice RL, Qi L. Aspects of the design and analysis of high-dimensional SNP studies for disease risk estimation. Biostatistics 2006; 7: 339-54.
196. Zhou X, Caligiuri G, Hamsten A, Lefvert AK, Hansson GK. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 108-14.
197. Binder CJ, Horkko S, Dewan A, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003; 9: 736-43.
198. Chyu KY, Nilsson J, Shah PK. Active and passive immunization for atherosclerosis. Curr Opin Mol Ther 2007; 9: 176-82.
199. Kuiper J, van Puijvelde GH, van Wanrooij EJ, et al. Immunomodulation of the inflammatory response in atherosclerosis. Curr Opin Lipidol 2007; 18: 521-6.
200. Mason JC. Statins and their role in vascular protection. Clin Sci (Lond) 2003; 105: 251-66.
201. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109: 18-26.
202. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84.
203. Di Napoli M. Benefits of statins in cerebrovascular disease. Curr Opin Investig Drugs 2004; 5: 295-305.
204. Moonis M, Fisher M. HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke. Expert Rev Neurother 2004; 4: 241-7.
205. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004; 35: 2902-9.
206. Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J. Statins and stroke prevention. Cerebrovasc Dis 2007; 24: 170-82.
207. Clark WM, Lutsep HL. Potential of anticytokine therapies in central nervous system ischaemia. Expert Opin Biol Ther 2001; 1: 227-37.
208. Frenkel D, Huang Z, Maron R, et al. Nasal vaccination with myelin oligodendrocyte glycoprotein reduces stroke size by inducing IL-10-producing CD4+ T cells. J Immunol 2003; 171: 6549-55.
209. Richard-Miceli C, Dougados M. Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience. BioDrugs 2001; 15: 251-9.
210. Siddiqui MA, Scott LJ. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs 2005; 65: 2179-208.
211. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed 2006; 8: 25.
212. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 2001; 57: 1428-34.